[go: up one dir, main page]

PT2408453T - Formulações oftálmicas de cetirizina e métodos de utilização - Google Patents

Formulações oftálmicas de cetirizina e métodos de utilização

Info

Publication number
PT2408453T
PT2408453T PT107539272T PT10753927T PT2408453T PT 2408453 T PT2408453 T PT 2408453T PT 107539272 T PT107539272 T PT 107539272T PT 10753927 T PT10753927 T PT 10753927T PT 2408453 T PT2408453 T PT 2408453T
Authority
PT
Portugal
Prior art keywords
cetirizine
methods
ophthalmic formulations
ophthalmic
formulations
Prior art date
Application number
PT107539272T
Other languages
English (en)
Original Assignee
Nicox Ophthalmics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Ophthalmics Inc filed Critical Nicox Ophthalmics Inc
Publication of PT2408453T publication Critical patent/PT2408453T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT107539272T 2009-03-17 2010-03-15 Formulações oftálmicas de cetirizina e métodos de utilização PT2408453T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16100609P 2009-03-17 2009-03-17
US17485009P 2009-05-01 2009-05-01

Publications (1)

Publication Number Publication Date
PT2408453T true PT2408453T (pt) 2022-04-05

Family

ID=42738180

Family Applications (2)

Application Number Title Priority Date Filing Date
PT107539272T PT2408453T (pt) 2009-03-17 2010-03-15 Formulações oftálmicas de cetirizina e métodos de utilização
PT211797519T PT3943069T (pt) 2009-03-17 2010-03-15 Formulações oftálmicas de cetirizina e métodos de utilização

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT211797519T PT3943069T (pt) 2009-03-17 2010-03-15 Formulações oftálmicas de cetirizina e métodos de utilização

Country Status (8)

Country Link
US (8) US9254286B2 (pt)
EP (2) EP3943069B1 (pt)
JP (8) JP6033677B2 (pt)
CA (1) CA2755679C (pt)
ES (1) ES2910374T3 (pt)
MX (1) MX2011009802A (pt)
PT (2) PT2408453T (pt)
WO (1) WO2010107689A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569273B2 (en) * 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
PT2408453T (pt) * 2009-03-17 2022-04-05 Nicox Ophthalmics Inc Formulações oftálmicas de cetirizina e métodos de utilização
WO2010141834A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
US10156386B2 (en) 2010-05-12 2018-12-18 Brooks Automation, Inc. System and method for cryogenic cooling
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
AU2013259872B2 (en) 2012-05-08 2018-06-28 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US11241426B2 (en) 2017-02-13 2022-02-08 Nitto Medic Co., Ltd. Aqueous composition for ophthalmic or nasal administration
CN110996954A (zh) * 2017-06-08 2020-04-10 眼科治疗有限责任公司 低剂量的溴莫尼定组合及其用途
EP3740193A4 (en) * 2018-01-15 2022-03-02 Seattle Gummy Company SEMI-SOLID ANTHIHISTAMINE COMPOSITIONS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
CN113712908A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 一种用于治疗过敏性结膜炎的组合物其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541989A (en) 1895-07-02 Joseph h
US569855A (en) 1896-10-20 Alvor butterfield
US440779A (en) 1890-11-18 Edward smith axd frederick smith
US518882A (en) 1894-04-24 Mary p
US610373A (en) 1898-09-06 Michele signorastbi
US452535A (en) 1891-05-19 Ehregott theodore winkler
US643692A (en) 1899-09-27 1900-02-20 Bernard H Speckbauch Printing-press.
US682794A (en) 1899-12-19 1901-09-17 Friedrich August Gasch Process of obtaining zinc solutions free from iron and manganese compounds.
US664960A (en) 1900-09-05 1901-01-01 John A Hill Oil-separator and automatic regulating-valve for refrigerating systems.
FI75816C (fi) * 1981-02-06 1988-08-08 Ucb Sa Foerfarande foer framstaellning av terapeutiskt aktiv 2-/4-(difenylmetyl)-1-piperazinyl/-aettiksyror eller dess amid.
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US5188826A (en) 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
AU636685B2 (en) 1989-12-18 1993-05-06 Alcon Laboratories, Inc. Compositions of antiallergics and antihistamines and methods for their use
EP0663828B1 (en) 1992-09-24 1998-09-09 Sepracor, Inc. Treating allergic rhinitis and asthma using (-) Cetirizine
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
EP0954318A1 (en) 1996-06-04 1999-11-10 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
CZ43299A3 (cs) 1996-08-16 1999-07-14 Schering Corporation Léčba alergií horních cest dýchacích kombinací antagonistů histaminového receptoru
EP0903151A1 (en) 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
US6103735A (en) 1998-10-09 2000-08-15 Schering Corporation Composition and method for treating allergic diseases
TR200201322T2 (tr) 1999-11-18 2002-11-21 Alcon, Inc. H1 antagonistleri ve güvenli bir steroid'in göz sağlık koşullarının tedavisi için kullanımı
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
JP2002025272A (ja) 2000-07-10 2002-01-25 Sharp Corp 半導体記憶装置およびその評価方法
AR035509A1 (es) 2000-12-21 2004-06-02 Alcon Inc Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento
US7243343B2 (en) 2001-04-10 2007-07-10 International Business Machines Corporation Method, compiler and platform independent framework for parsing and generating data structures
US6985573B2 (en) 2001-04-13 2006-01-10 General Instrument Corporation Customer premises equipment that can support multiple call control languages or multiple call agents
US6592896B2 (en) 2001-08-06 2003-07-15 The Quigley Corporation Medicinal composition and method of using it
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
DK1467762T3 (da) 2001-12-05 2006-04-10 Alcon Inc Anvendelse af en H1-antagonist og rimexolon som et sikkert steroid til behandling af rhinitis
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20040019882A1 (en) 2002-07-26 2004-01-29 Haydt Robert J. Scalable data communication model
RU2220740C1 (ru) 2002-08-30 2004-01-10 Гапонюк Петр Яковлевич Средство для лечения аллергического ринита и аллергического конъюнктивита
JP2004168709A (ja) 2002-11-20 2004-06-17 Nidek Co Ltd 抗アレルギー点眼点鼻用組成物
WO2004069157A2 (en) 2003-01-17 2004-08-19 Ophthalmic Research Associates, Inc. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
US20050090527A1 (en) 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
US20040198743A1 (en) 2003-01-31 2004-10-07 Schering Corporation Methods for treating allergic skin and allergic ocular conditions using combinations of histamine receptor antagonists
US20050023974A1 (en) 2003-08-01 2005-02-03 Universal Display Corporation Protected organic electronic devices and methods for making the same
WO2005037592A1 (de) 2003-09-23 2005-04-28 Daimlerchrysler Ag Verfahren und vorrichtung zur erkennung von spurwechselvorgängen für ein fahrzeug
WO2005030331A1 (en) 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
US20060263350A1 (en) 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
US20050239745A1 (en) 2004-03-03 2005-10-27 Ophthalmic Research Associates, Inc. Novel topical ophthalmic formulations
US20050255154A1 (en) 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
US8372814B2 (en) 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
PE20060484A1 (es) 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
JP3897777B2 (ja) 2004-07-23 2007-03-28 株式会社半導体理工学研究センター パルスベース通信システム
WO2006010294A1 (fr) 2004-07-26 2006-02-02 Quanta Display Inc. Dispositif d'affichage a cristaux liquides
US7337789B2 (en) 2004-07-27 2008-03-04 Minel Kupferberg Cleaning apparatus for exhaust system and method
US7307535B2 (en) 2004-07-27 2007-12-11 Datamars S.A. Air coil RF transponder and method of making same
AU2005256105B8 (en) 2004-07-30 2008-10-02 Blackberry Limited Method and apparatus for provisioning a communications client on a host device
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
EP1868578A2 (en) * 2005-03-23 2007-12-26 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations
JP2007012937A (ja) 2005-06-30 2007-01-18 Seiko Epson Corp 表示ドライバ
PL1919450T3 (pl) 2005-09-01 2014-11-28 Meda Ab Kompozycja liposomowa zawierająca lek przeciwhistaminowy i kortykosteroid oraz jej zastosowanie do wytwarzania leku do leczenia nieżytu nosa i chorób spokrewnionych
PL3150209T3 (pl) 2006-03-31 2020-03-31 Vistakon Pharmaceuticals, Llc Leczenie alergii oczu
US20080008592A1 (en) 2006-06-27 2008-01-10 Societe De Commercialisation Des Produits De La Recherche Appliquee - Socpra-Sc Method and apparatus for controlling tonal noise from subsonic axial fans
KR100834625B1 (ko) 2006-07-27 2008-06-02 삼성전자주식회사 비디오 인코딩 데이터율 제어를 위한 실시간 장면 전환검출 방법
EP3210594B1 (en) 2006-09-29 2023-09-13 Johnson & Johnson Vision Care, Inc. Methods and ophthalmic devices used in the treatment of ocular allergies
JP2010523695A (ja) * 2007-04-11 2010-07-15 アルコン リサーチ， リミテッド アレルギー性鼻炎およびアレルギー性結膜炎を処置するためのＴＮＦαのインヒビターおよび抗ヒスタミン薬の使用
JP2010531898A (ja) * 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
PT2408453T (pt) * 2009-03-17 2022-04-05 Nicox Ophthalmics Inc Formulações oftálmicas de cetirizina e métodos de utilização

Also Published As

Publication number Publication date
JP2020117545A (ja) 2020-08-06
US20160106666A1 (en) 2016-04-21
JP2018141022A (ja) 2018-09-13
EP2408453A1 (en) 2012-01-25
JP2016190879A (ja) 2016-11-10
US11617749B2 (en) 2023-04-04
JP2015007136A (ja) 2015-01-15
US8829005B2 (en) 2014-09-09
WO2010107689A1 (en) 2010-09-23
CA2755679A1 (en) 2010-09-23
JP6033677B2 (ja) 2016-11-30
EP2408453A4 (en) 2013-08-28
JP2012520882A (ja) 2012-09-10
CA2755679C (en) 2017-09-12
US10675279B2 (en) 2020-06-09
US9993471B2 (en) 2018-06-12
US20200297719A1 (en) 2020-09-24
US20210290617A1 (en) 2021-09-23
EP3943069B1 (en) 2024-11-27
EP2408453B1 (en) 2022-01-05
PT3943069T (pt) 2025-02-21
US20200405711A1 (en) 2020-12-31
US20180280383A1 (en) 2018-10-04
JP7088980B2 (ja) 2022-06-21
US10987352B2 (en) 2021-04-27
JP2021138760A (ja) 2021-09-16
EP3943069A1 (en) 2022-01-26
JP2016190878A (ja) 2016-11-10
ES2910374T3 (es) 2022-05-12
US11918573B2 (en) 2024-03-05
US20130252971A1 (en) 2013-09-26
JP6893573B2 (ja) 2021-06-23
JP6449202B2 (ja) 2019-01-09
US9254286B2 (en) 2016-02-09
JP6144393B2 (ja) 2017-06-07
US9750684B2 (en) 2017-09-05
JP2020117544A (ja) 2020-08-06
MX2011009802A (es) 2011-11-02
US20100240625A1 (en) 2010-09-23
US20170182035A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
EP2437743A4 (en) OPHTHALMIC FORMULATIONS OF FLUTICASONE AND METHODS OF USE
PT2408453T (pt) Formulações oftálmicas de cetirizina e métodos de utilização
IL256924B (en) Prebiotic formulations and methods of using them
EP2408302A4 (en) OPHTALMIC FORMULATIONS OF KTOTICENE AND METHODS OF USE
EP2437602A4 (en) OPHTHALMIC FORMULATIONS, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THEIR USE
EP2448581A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF USE THEREOF
GB2509641B (en) Patient interface and aspects thereof
GB2494493B (en) Patient interface and aspects thereof
HK1173654A1 (zh) 治療化合物及相關的使用方法
EP2547340A4 (en) OPHTHALMIC FORMULATIONS OF CETIRICINE AND METHOD FOR THEIR USE
EP2637684A4 (en) BUFFERED OPHTHALMIC COMPOSITIONS AND USER METHOD THEREFOR
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
GB0920258D0 (en) New medical agents and use thereof
ZA201202892B (en) Ophthalmic formulation and method of manufacture thereof
IL217135A0 (en) Stabilized herbicidal formulations and methods of use
HK1174620A1 (zh) 吲唑基取代的二氫異噁唑並吡啶及其使用方法
IL226134A0 (en) Ophthalmic preparations with buffer and methods for their preparation